According to the Futu Financial app, Besunyen (00926) released its six-month performance ending on June 30, 2024. The group achieved sustained operating revenue of RMB 0.254 billion, a year-on-year decrease of 25.83%. The net profit attributable to owners of the company was RMB 7.813 million, compared with a loss of RMB 0.116 billion in the same period last year. The basic earnings per share was 6.39 cents, and the proposed interim dividend was HKD 0.9 per share.

In the first half of 2024, the group's revenue was RMB 0.254 billion, a year-on-year decrease of 25.8%. Among them, the revenue from four teas (Besunyen brand Changrun tea, Changjing tea, Xianxian tea, and Qingyuan tea) was RMB 0.135 billion, a year-on-year decrease of 17.1%, and the revenue from weight loss pharmaceuticals was RMB 82.1 million, a year-on-year decrease of 29.3%. In the first half of 2024, the group achieved a comprehensive revenue of RMB 8.5 million, a 66.7% increase from the comprehensive operating revenue of RMB 5.1 million in the first half of 2023.

In the first half of 2024, the group continued to pursue a stable and progressive work approach, continued to promote cost reduction and efficiency improvement, and further optimized the organizational structure to improve operational efficiency. With the advantage of a group joint venture company formed by former employees of the group as a new business partner for the group, the group has successfully undertaken the distribution, agency, and service work of Besunyen products. Through the joint efforts of the group and the new business partners, the group's offline OTC business has achieved a smooth transition and robust development, and the online operation model of the agency business has become more mature, helping the group to gradually improve online operational efficiency. The new business partner model has effectively promoted the overall operational quality of the group.

In the first half of 2024, the group continued to focus on the four teas of functional health tea and weight loss pharmaceuticals (i.e. Orlistat), and continuously expanded the promotion of the group's products and brands through high-speed rail, screen media, Xiaohongshu, influencers, TikTok, and Kuaishou, among other media. In the first half of 2024, the group's offline sales business covered nearly 0.29 million non-prescription drug (OTC) pharmacies and third-party medical terminals in 31 provinces, autonomous regions, and municipalities across the country through new business partners. The group's online e-commerce business opened 63 stores on 18 e-commerce platforms for the sales of four teas, Orlistat, and other products of the group. The group actively embraces the development of new retail sales by continuously attempting new methods on platforms such as Douyin, Kuaishou, O2O, and B2C. Through these mature and innovative channels, the group's new products can enter the market more quickly, thereby maintaining the industry-leading position of the group's product sales.